LENZ Therapeutics, Inc. 8-K

What Happened LENZ Therapeutics, Inc. filed an 8-K (dated July 2, 2026) reporting that director Dr. Zach Scheiner resigned from the Company's Board of Directors and all board committees effective June 30, 2026. The company stated the resignation was not due to any dispute or disagreement with the Company. As a result, the Board reduced its size to six members. On June 30, 2026, the Board appointed Jeff George to the Audit Committee.

Key Details

• Dr. Zach Scheiner resigned effective June 30, 2026; resignation was not due to any dispute or disagreement.
• Board size was decreased to six members following the resignation.
• Jeff George was appointed to the Audit Committee effective June 30, 2026; Audit Committee members are now Shelley Thunen, Frederic Guerard, and Jeff George.
• The 8-K was signed by Daniel Chevallard, Chief Financial Officer, and filed on July 2, 2026.

Why It Matters Board membership and committee composition affect corporate governance and oversight—especially the Audit Committee, which oversees financial reporting and external audit matters. This filing signals a change in governance personnel but reports no disagreement or operational dispute. For investors, the change appears administrative and shows the Board promptly filled a committee vacancy; there were no disclosed changes to executive officers or financial results in this filing.